Novartis AG, of Basel, Switzerland, said the New England Journal of Medicine published the results from two pivotal phase III studies evaluating the interleukin-17A (IL-17A) inhibitor secukinumab, which met all primary and key secondary endpoints in the ERASURE and FIXTURE studies, including Psoriasis Area and Severity Index 75 and 90 and Investigator's Global Assessment modified 2011 0/1 responses.